Advertisement
UK markets close in 7 hours 55 minutes
  • FTSE 100

    8,129.01
    +50.15 (+0.62%)
     
  • FTSE 250

    19,706.33
    +104.35 (+0.53%)
     
  • AIM

    755.37
    +2.25 (+0.30%)
     
  • GBP/EUR

    1.1652
    -0.0004 (-0.04%)
     
  • GBP/USD

    1.2503
    -0.0008 (-0.06%)
     
  • Bitcoin GBP

    51,549.95
    +172.51 (+0.34%)
     
  • CMC Crypto 200

    1,387.69
    -8.85 (-0.63%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    84.07
    +0.50 (+0.60%)
     
  • GOLD FUTURES

    2,356.90
    +14.40 (+0.61%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,656.45
    +371.91 (+2.15%)
     
  • DAX

    18,013.44
    +96.16 (+0.54%)
     
  • CAC 40

    8,043.83
    +27.18 (+0.34%)
     

A Review of Novo Nordisk’s Modern Insulin

A Review of Novo Nordisk’s Modern Insulin

Novo Nordisk’s (NVO) modern insulins include NovoRapid, Levemir, and NovoMix. In 4Q17, its modern insulins generated revenues of 10.4 billion Danish kroner, which is a ~9% YoY (year-over-year) decline in local currency.